Risks Versus Benefits in Combining Immunotherapies
Combining two checkpoint blockades can be very efficacious in treating metastatic melanoma, but the benefits come with increased risk of adverse events, too.
How to Manage ICANS in Patients With Hematologic Cancers
Nurses, APPs Critical to Getting Oncology Patients Newer Therapies
Managing Infection Risk With Bispecific Antibodies in Myeloma
Managing CRS in Hematologic Cancers: A Nursing Perspective